Prostate Cancer Articles & Analysis

Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University School of Medicine presented results from the first 10 participants at the 2021 Annual Prostate Cancer Foundation Scientific Retreat. The poster presented featured early results from “A Feasibility Study to Deplete Non-Essential Amino Acids in Patients ...

By Filtricine, Inc.

Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...

By MediWales

This is my first year with Intelex and what better way to get to know my fellow coworkers than by growing moustaches together? Yes, that’s right: the Intelex family participated in this year’s Movember. Ah, how my upper lip does miss its fuzzy warmth (sadly I had to say goodbye to it on December 1st). In addition to Intelexians raising $2,635 throughout the month of November to ...

By Intelex Technologies Inc.

Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...

By Nanostics Inc.

Ryan Rhodes, new CEO of EDAP USA was featured in MDDI this week. Rhodes hales from Intuitive Surgical where he helped build the DaVinci Robot brand. He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, ...

By EDAP TMS

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique ...

By Cancer Targeted Technology

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...

By miR Scientific, LLC

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in-person in ...

By Blue Earth Diagnostics

NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...

By miR Scientific, LLC

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...

By Bayer AG

NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...

By miR Scientific, LLC

Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. Seattle, Washington, June 2021. Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical ...

By Cancer Targeted Technology

C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used ...

By C4 Imaging LLC

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends the use of IsoPSA as an option to ...

By Cleveland Diagnostics, Inc.

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to ...

By BriaCell Therapeutics Corp.

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...

By miR Scientific, LLC

Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall ...

By Bayer AG

With Halloween in the dust and an honourable mention to Intelex’s very own Brandyn Berry for the stylin’ Michael Jackson costume he moon-walked through the office last Friday, today marks the start of the Movember fundraising campaign, both globally and here at Intelex. For those who haven’t heard of Movember, it’s a campaign that raises funds and awareness for prostate ...

By Intelex Technologies Inc.

Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...

By Bayer AG

C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...

By C4 Imaging LLC